A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects

• Status: Completed
• Trial end date: 2014-04-08
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, randomized, single dose, two-sequence two-period crossover study, separated by 7 days washout interval from the first Study Drug Administration. This study is conducted to determine the bioequivalence of cefadroxil from DURICEF™ film coated tablets manufactured by Smithkline Beecham Egypt, LLC affiliated co. to GalaxoSmithKline (GSK) and cefadroxil from BIODROXIL™ film coated tablets manufactured by Kahira Pharm &Chem .Ind. Co . for Novartis Pharma (NP) after a single oral dose administration of each to healthy adult subjects under fasting conditions. In Period 1, subjects will be randomized to receive cefadroxil tablet manufactured by either GSK or NP. Following a washout of at least 7 days, subjects will be crossed over in Period 2 to receive the cefadroxil tablet that they did not receive in Period 1. DURICEF is a trademark of the GSK group of companies. BIODROXIL is a trademark of Sandoz.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Cefadroxil

Criteria

Inclusion Criteria:

• Healthy male or female, age 18 to 55 years, inclusive.

• Body weight within 15 percent of normal range according to the accepted normal values for body mass index (BMI).

• Medical demographics without evidence of clinically significant deviation from normal medical condition.

• Results of clinical laboratory test are within the normal range or with a deviation that is not considered clinically significant by principal investigator.

• Subject does not have allergy to the drugs under investigation.

Exclusion Criteria:

• Subjects with known allergy to the products tested.

• Subjects whose values of BMI were outside the accepted normal ranges.

• Female subjects who were pregnant, nursing or taking birth control pills.

• Medical demographics with evidence of clinically significant deviation from normal medical condition.

• Results of laboratory tests which are clinically significant.

• Acute infection within one week preceding first study drug administration.

• History of drug or alcohol abuse.

• Subject does not agree not to take any prescription or non-prescription drugs within two weeks before first study drug administration and until the end of the study.

• Subject is on a special diet (for example subject is vegetarian).

• Subject does not agree not to consume any beverages or foods containing methyl-xanthenes e.g. caffeine (coffee, tea, cola, chocolate etc.) 48 hours prior to the study administration of either study period until donating the last sample in each respective period.

• Subject does not agree not to consume any beverages or foods containing grapefruit 7 days prior to first study drug administration until the end of the study.

• Subject has a history of severe diseases which have direct impact on the study.

• Participation in a bioequivalence study or in a clinical study within the last 6 weeks before first study drug administration.

• Subject intends to be hospitalized within 6 weeks after first study drug administration.

• Subjects who, through completion of this study, would have donated more than 500 milliliter (mL) of blood in 7 days, or 750 mL of blood in 30 days, 1000 mL in 90 days, 1250 mL in 120 days, 1500 mL in 180 days, 2000 mL in 270 days, 2500 mL of blood in 1 year.